October 1, 2012
Bookmark and Share  



This month we have several new and important items for you at the HCV and HBV Websites:


1. October 2012 HCV Advocate

In This Issue:

  • Advances in Liver Transplantation
    Alan Franciscus, Editor-in-Chief
    This article highlights three recent studies – the first use of a DDA post HCV treatment, a Monoclonal Antibody to prevent HCV reinfection after a liver transplant, and long-term survival of people who receive a live liver donation

  • HCV Snapshots
    Lucinda K. Porter, RN
    Lucinda recaps three studies: HCV treatment in children, heart disease and HCV, and access to care for people with HBV and HCV

  • HealthWise: - When HCV Treatment is Over
    Lucinda K. Porter, RN

    This month's Healthwise discusses the more serious and on-going side effects that may linger long after treatment ends

  • Type 2 Diabetes and Insulin Resistance in People with HCV – Part 1
    Liz Highleyman

    The first part of an article on diabetes and insulin resistance discusses the types of diabetes and insulin resistance, causes, symptoms and the possible HCV connection

2. Needy Meds.org Webinars – do you or your clients need help with paying for prescription medications? NeedyMeds.org is offering Webinars on the following dates to explain the benefits of using their patient assistance programs to access free medications and discounts for physician prescriptions:

Oct 3

Oct 17

3. HBV Journal Review by Christine Kukka –In this month's column Chris reviews the following studies:

  • Researchers Say Young, Immune-Tolerant Patients Should Be Treated

  • Antiviral-Induced HBeAg Loss in Young Patients May Not Last

  • Interferon More Effective in Younger Patients, and When Extended to 72 Weeks

  • Treatment with Antiviral First, Followed by Interferon, Yields Best Results

  • One-Third of Babies Born to Infected Mothers Do Not Receive Proper Follow-up

  • Diabetes/Elevated Blood Sugar Increases Cirrhosis Risk

  • Age and High Viral Loads Increase Fibrosis Risk in HBeAg-Positive Patients

  • HBV-Infected Women Have Higher Mercury Levels in the U.S.

  • Nationwide Study Documents High Cost of Viral Hepatitis

  • Half of HBeAg-Positive Patients Lose HBeAg after Three Years on Entecavir

  • Entecavir Is More Cost-Effective than Adefovir for HBV Patients with Cirrhosis

  • Study Shows Tenofovir Effective in Adefovir-Resistant Patients

4. HCV Drug Pipelinehas been updated to include the most recent news items. 


5. Factsheets and Guidescheck out the various fact sheets and guides that have been updated to include the latest information. 




6. Training ScheduleDon’t forget to keep checking our Upcoming Training Workshop Schedules to see if we will be in your neighborhood soon!



Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at www.help4hep.org  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 


7. Top News (Blog) from the hepatitis blog includes: 

AMA pushes for safe injecting trial
October 1

The Next Big Thing in Biotech: Hepatitis Drugs
September 29

Don't rule out IFN/ribavirin for HIV patients with hep C cirrhosis: study
September 28

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs
September 28

VIEW : Intellectual bankruptcy — Syed Kamran Hashmi
September 27

Achillion heralds upbeat hepatitis C results as it rushes through Phase II Read more: Achillion heralds upbeat hepatitis C results as it rushes through Phase II
September 27

Treating Hepatitis C Infection in Prison is Good Public Policy
September 27

Interferon Free HCV Treatment: Simeprevir and ALS-2200 Enter Phase 2 All-oral Studies
September 26

Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158
September 25

Ethicists question doctor's pitch for a hepatitis C drug trial
September 25

Manitoba Adds Victrelis Triple to Pharmacare
September 25

Lawsuit seeks needle exchange programs for prisons
September 25


 and much, much more…..




Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.